Skip to main content

Advertisement

SpringerLink
Log in

Voriconazole plasma levels in children are highly variable

  • Brief Report
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cohen-Wolkowiez M, Maan C, Benjamin DK Jr et al (2009) Pediatric antifungal agents. Curr Opin Infect Dis 22:553–558

    Article  PubMed  Google Scholar 

  2. Pascual A, Calandra T, Bolay S et al (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201–211

    Article  CAS  PubMed  Google Scholar 

  3. Andes D, Pascual A, Marchetti O (2009) Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53:23–34

    Google Scholar 

  4. Walsh TJ, Karlsson MO, Driscoll T et al (2004) Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple dose administration. Antimicrob Agents Chemother 48:2166–2172

    Article  CAS  PubMed  Google Scholar 

  5. Karlsson MO, Lutsar I, Miligan PA (2009) Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 53:935–944

    Article  CAS  PubMed  Google Scholar 

  6. Neely M, Rushing T, Kovacs A et al (2010) Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 50:27–36

    Article  CAS  PubMed  Google Scholar 

  7. Van der Linden JWM, Bruggeman RJM, Knoop J et al (2009) Therapeutic drug monitoring of voriconazole in pediatric patients. Mycoses 52(Suppl 1):23

    Google Scholar 

  8. Spriet I, Annaert P, Meersseman P et al (2009) Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 63:767–770

    Article  CAS  PubMed  Google Scholar 

  9. Purkins L, Wood N, Ghahramani P et al (2002) Pharmacokinetics and safety of voriconazole following intravenous to oral dose escalation regimens. Antimicrob Agents Chemother 46:2546–2553

    Article  CAS  PubMed  Google Scholar 

  10. Yanni SB, Annaert PP, Augustijns P et al (2010) In vitro hepatic metabolism explains higher clearance of voriconazoel in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Disp 38:25

    Article  CAS  Google Scholar 

  11. Vfend EMEA, European Assessment Report. Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/vfend/404901en8.pdf. Accessed 29 January 2010

  12. Malani AN, Aronoff DM (2008) Voriconazole-induced photosensitivity. Clin Med Res 6:83–85

    Article  PubMed  Google Scholar 

  13. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A (2003) Co-administration of voriconazole and phenytoin: pharmacokinetic interaction, safety and toleration. Br J Clin Pharmacol 56(S1):37–44

    Article  CAS  PubMed  Google Scholar 

Download references

Transparency Declaration

None to declare.

Author information

Authors and Affiliations

  1. Pharmacy Department, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium

    I. Spriet, K. Cosaert & L. Willems

  2. Pediatric Oncology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium

    M. Renard & A. Uyttebroeck

  3. Pediatric Immunodeficiencies, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium

    I. Meyts

  4. Pediatric Pneumology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium

    M. Proesmans

  5. Surgical Intensive Care Unit, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium

    G. Meyfroidt

  6. Centre for Clinical Pharmacology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium

    J. de Hoon & R. Verbesselt

Authors
  1. I. Spriet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Cosaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Renard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Uyttebroeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Meyts
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Proesmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Meyfroidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. de Hoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Verbesselt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L. Willems
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Spriet.

Additional information

Sources of support: The quantification of voriconazole plasma levels was funded by an independent grant from Pfizer Inc., Belgium.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spriet, I., Cosaert, K., Renard, M. et al. Voriconazole plasma levels in children are highly variable. Eur J Clin Microbiol Infect Dis 30, 283–287 (2011). https://doi.org/10.1007/s10096-010-1079-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-010-1079-8

Keywords

Search

Navigation